News

Agendia, Inc.: Agendia to Present FLEX Study Data on Impact of BluePrint at ESMO Breast Cancer 2025
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among MammaPrint® High Risk HR+ HER2- breast cancers, supporting more personalized treatment strategies Agendia ...
Medical Dialogues4d
S.T.O.N.E. Score Effective in Predicting Stone-Free Outcomes After Ureteral Lithotripsy: Study Shows
Yemen: A new study published in Research and Reports in Urology has demonstrated the clinical relevance of the S.T.O.N.E.